Elevance Health Reaffirms Full-Year 2026 EPS Guidance of at Least $20.10, Shares Jump 6%

Elevance Health filed an 8-K on September 10, 2026, disclosing that company officers speaking with investors and analysts in the coming weeks will reaffirm full-year 2026 shareholders' earnings guidance of at least $20.10 per diluted share. That figure includes approximately $6.90 per diluted share of net unfavorable items, while adjusted earnings guidance holds at at least $27.00 per diluted share. The company also reaffirmed its full-year 2026 benefit expense ratio guidance at 90.2%, plus or minus 50 basis points.

The disclosure came ahead of investor meetings including a presentation at the Wells Fargo conference, where management signaled its growth plan remains on track. Shares of ELV climbed roughly 6% on the day, outperforming broader sector peers including UnitedHealth and Cigna. The stock's move reflected investor relief that guidance was held firm despite ongoing concerns about Medicaid cost pressures.

The reaffirmed adjusted EPS target of at least $27.00 is consistent with what the company reported at its second-quarter 2026 earnings, when it raised that figure and expressed confidence in returning to at least 12% adjusted EPS growth in 2027. Management has pointed to AI-driven margin initiatives and new behavioral-health leadership as contributors to the forward outlook, while noting that Medicaid carries a negative operating margin of approximately negative 1.75% for the full year.